Heft Nr. 1-2/2026
Anzeigenschluss: 13.01.2026
Erscheinungstermin: 05.02.2026
Gynäkoonkologie
Brustkrebs
Reimer T et al.
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
Ovarialkarzinom
Oza AM et al.
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label,randomised, phase 3 trial
Zervixkarzinom
Mayadev J et al.
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
Brustkrebs
Tolaney M et al.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
frühes Mammakarzinom
L. Bähner, N. Ditsch
Individualisierte und innovative Behandlungsansätze beim frühen Mammakarzinom
Kongressbericht: SABCS
Highlights vom San Antonio Breast Cancer Symposium 2025
Hämatologie
AML
Daver N et al.
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
DLBCL
Michot JM et al.
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial
MCL
Wang M et al.
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Kongressbericht: ASH
Neue Daten vom 67th ASH Annual Meeting
Allgemeine Onkologie
Krebsüberlebende
Berkeley M et al.
Baseline characteristics of survivors, primary care clinicians, and oncologists in a randomized trial of a shared care, self-management intervention for cancer survivors
Corona-Impfung
Grippin AJ et al.
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Patient-Reported Outcomes
Huang RS et al.
Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis
PREM
Patient Reported Experience Measurements - Chancen und Herausforderungen
Geriatrie
Geriatrische Expertise in die Onkologie integrieren
Gastroonkologie
Kolonkarzinom
Assenat E et al.
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Pankreaskarzinom
Fietkau R et al.
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
HCC
Shi Y et al.
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Uroonkologie
Urothelkarzinom
Powles TB et al.
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase IIIEV-302/KEYNOTE-A39 trial
Prostatakarzinom
Fizazi K et al.
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Prostatakarzinom
Agarwal N et al.
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Supportivtherapie
Pflegegeleitetes Symptommanagement
Pedersen M, Larsen MT, Kornblit BT, et al.
Effects of nurse-led symptom management in chronic myeloid malignancies: a randomized trial
Körperliche Bewegung bei HSCT
Dreyling E et al. A
A Randomized Controlled ‘REAL-FITNESS’ Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma
Fortbildung
Notfälle unter Immuntherapie
Pneumoonkologie
NSCLC
He J et al.
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer
NSCLC
Spigel DR et al.
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
NSCLC
Yang JCH et al.
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
*Die Redaktion behält sich aktuelle Änderungen vor.